Drugs & Targets ArsenalBio’s lead product advances to clinical manufacturing following Thermo Fisher collaboration March 31, 2023Vol.49 No.13
Drugs & Targets FDA releases draft guidance aimed at improving oncology clinical trials for accelerated approval March 24, 2023Vol.49 No.12
Drugs & Targets FDA grants accelerated approval to Zynyz for metastatic or recurrent locally advanced Merkel cell carcinoma March 24, 2023Vol.49 No.12
Drugs & Targets ACS & Winship Cancer Institute partner to accelerate cancer research in Georgia March 24, 2023Vol.49 No.12
Drugs & Targets FDA approves Tafinlar + Mekinist for pediatric patients with low-grade glioma with a BRAF V600E mutation March 17, 2023Vol.49 No.11
Drugs & Targets Prelude Therapeutics to collaborate with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic cancers March 17, 2023Vol.49 No.11
Drugs & Targets FDA broadens indication for Verzenio in HR+, HER2-, node-positive, high-risk early breast cancer March 10, 2023Vol.49 No.10
Drugs & Targets FDA approves label expansion for VENTANA PD-L1 assay to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo March 10, 2023Vol.49 No.10
Drugs & Targets FDA updates mammography regulations to require reporting of breast density information and enhance facility oversight March 10, 2023Vol.49 No.10
